ArticleDiscover endocrinology and metabolism2025
Associations of urinary zinc with incident peripheral artery disease and amputation in the Strong Heart Study.
Article in Discover endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Type 2 diabetes mellitus and zinc dysregulation: From basic and epidemiological evidence to interventions.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Urinary zinc has been associated with cardiometabolic endpoints, including diabetes and cardiovascular disease, but evidence for peripheral artery disease (PAD) is limited. We evaluated prospective associations between urinary zinc and incident PAD and amputation events in the Strong Heart Study (SHS), a large epidemiological cohort of American Indian adults in the United States. Methods: A total of 2,045 PAD-free and 2,180 amputation-free participants were included at baseline (1989-91), (mean age 56 years, 61% female). PAD (defined as ankle brachial index < 0.9 or > 1.4) and diabetes-related amputation events were collected through two SHS visits over 10 years. Odds ratios (OR) of PAD and amputation by baseline urinary zinc levels adjusted by creatinine (µg/g) were evaluated with progressively adjusted logistic regression models. Results: 344 participants developed PAD and 23 underwent diabetes-related amputations. The ORs (95% CI) per one interquartile range increment in baseline urinary zinc levels were 1.29 (1.10, 1.51) and 2.36 (1.43, 3.90) for incident PAD and amputation, respectively, when adjusting for sociodemographic and clinical risk factors. Estimates were attenuated by further adjusting for diabetes status (OR: 1.16 (0.98, 1.38) for incident PAD), and fasting plasma glucose (OR: 1.09 (0.91, 1.31) and OR: 1.39 (0.76, 2.54) for incident PAD and amputation, respectively). Associations between urinary zinc levels and incident PAD were stronger among participants with diabetes at baseline (OR: 1.43 (1.11, 1.86)). Conclusions: We identify prospective associations between higher urinary zinc levels and increased risk of PAD and amputation in the SHS, with stronger effects among participants with diabetes. Supplementary Information: The online version contains supplementary material available at 10.1007/s44417-025-00005-0.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.